Treatment of Relapsed/Refractory Myeloma (excluding T-cell redirection therapy)
Characterization and management of ocular events in patients (pts) treated with belantamab mafodotin (belamaf) plus bortezomib and dexamethasone (BVd) in the DREAMM-7 study
Vania Hungria, MD, PhD
Associate Professor
Department of Hematology, Clinica São Germano, São Paulo, Brazil
Sao Paulo, United States